Gemini Symbicort pMDI
Study identifier:D5896C00001
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A rand, doubleblind, activecontrolled, parallel-grp,singledummy, multicenter,12 wk study to assess the effic.&safety of Symbicort pMDI 2x160/4.5mcg QD compared to Symb. pMDI 2x80/4.5mcg QD, Symb. pMDI 2x80/4.5mcg bid and to budesonide pMDI 2x160 mcg QD in asthmatic sub's12yrs and over
Medical condition
Mild or moderate asthma
Phase
Phase 3
Healthy volunteers
No
Study drug
budesonide/formoterol (Symbicort)
Sex
All
Actual Enrollment
615
Study type
Interventional
Age
12 Years +
Date
Study Start Date: 01 Oct 2003
Primary Completion Date: -
Study Completion Date: 01 Feb 2005
Study design
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verification:
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: 1 | - |
Contacts
Investigators
Principal Investigator
Liza O'Dowd
AstraZeneca
